Tag Archives: #Warning Letters

FDA’s OPDP Issues Second Regulatory Action Letter of 2023

In what has been a long period of relative low activity, FDA’s OPDP has taken the opportunity to remind us that low enforcement does not mean no enforcement when it comes to promotional speech by pharmaceutical companies. This past June … Continue reading

Posted in FDA Policy, Warning Letters | Tagged , , | Comments Off on FDA’s OPDP Issues Second Regulatory Action Letter of 2023